There is a growing need for more accurate and reproducible assessment and quantification of Interstitial Lung Disease.

Brainomix’ e-ILD solution has been trained to characterize and quantify pulmonary fibrosis and other characteristics using thousands of cases from leading academic institutions.

Automated biomarkers such as those available through e-ILD have been shown to correlate with mortality, and to predict changes in FVC at earlier timepoints.